iN Therapeutics Co.,Ltd. announced that it has received KRW 26,000,000,000 in a bridge round of funding on February 7, 2022. The transaction included participation from new investors InterVest Co., Ltd., STIC Ventures, Inc., returning investors Yuanta Investment, Aju IB Investment Co., Ltd., Kiwoom Investment Co., Ltd., Timefolio Asset Management Co.,Ltd, Shinhan Capital, Investment Arm, DAYLI Partners Co., Ltd., and E& Venture Partners.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,855 KRW | +6.73% | +6.13% | +3.82% |
1st Jan change | Capi. | |
---|---|---|
+3.82% | 244M | |
-6.66% | 112B | |
-7.01% | 84.95B | |
+16.30% | 61.67B | |
+4.89% | 60.84B | |
+8.05% | 42.24B | |
+8.68% | 41.01B | |
+17.51% | 34.74B | |
+2.47% | 24.47B | |
-6.13% | 21.86B |
- Stock Market
- Equities
- A027360 Stock
- News Aju IB Investment Co., Ltd.
- IN Therapeutics Co.,Ltd. announced that it has received KRW 26 billion in funding from a group of investors